The Global Health Body Sounds Concern Over Severe Lack of Obesity Medications
Under a tenth of people eligible to benefit from GLP-1 drugs such as Wegovy have access to them, caution the global health agency as it publishes its first advice on the therapies.
With in excess of 1,000,000,000 individuals worldwide currently living with obesity, it is advocating for increased and just access to GLP-1 medication.
Per estimates, more than two billion will be obese by 2030 without intervention.
"Our new guidelines affirms that excess weight is a long-term condition that can be treated with thorough and ongoing care," remarked its chief Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and supply-chain constraints are major obstacles to universal availability to the treatments that can assist patients in reducing substantial body mass, says the organization.
Weight-Loss Drug Scarcity
Even in the current best projected scenario, the supply of these medications could only cover around 100 million people – under 10% of eligible patients, as stated by the health organization.
The advice encourages countries and companies to expand access, through measures including licensing agreements.
Exclusive production rights on a key compound – the core ingredient of a leading brand – is scheduled to end in several nations in 2026.
How Weight-Loss Injections Work
The injections replicate a natural hormone to slow digestion, reduce hunger and boost feelings of fullness so individuals consume fewer calories.
People typically begin shedding pounds after several weeks of beginning the once-weekly jabs.
Studies points to patients may regain a significant portion within a year of stopping the treatment, when their typical hunger come back.
To be carrying excess weight elevates your likelihood for developing medical conditions, like diabetes, heart disease, stroke, and certain malignancies.
Obesity affects individuals in every country and was associated with millions of fatalities worldwide in 2024, as per the health agency.